ArticleOncotarget2017
The relationship between tumor markers and pulmonary embolism in lung cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review.Frontiers in cardiovascular medicine · 2021Pooled it
- Clinical features of pulmonary embolism in patients with lung cancer: A meta-analysis.PloS one · 2019Pooled it
- Comprehensive review of pulmonary embolism imaging: past, present and future innovations in computed tomography (CT) and other diagnostic techniques.Japanese journal of radiology · 2025Review
- Incidence of pulmonary embolism and its risk factors in lung cancer patients: a systematic review and meta-analysis.Discover oncology · 2025Article
- Characteristics and risk factors for advanced lung cancer with pulmonary embolism: A cross-sectional, case-control study.The clinical respiratory journal · 2023Article
- Noninvasive optical monitoring of pulmonary embolism: a Monte Carlo study on visible Chinese human thoracic tissues.Journal of biomedical optics · 2023Article
- Characteristics and outcomes of cancer patients who develop pulmonary embolism: A cross-sectional study.Oncology letters · 2022Article
- Circulating D-Dimers Increase the Risk of Mortality and Venous Thromboembolism in Patients With Lung Cancer: A Systematic Analysis Combined With External Validation.Frontiers in medicine · 2022Article
- Changes of Tumor Markers in Patients with Lung Cancer after Immunotherapy and Their Link with Inflammation in the Body.Computational and mathematical methods in medicine · 2022Article
- Optimal authoritative risk assessment score of Cancer-associated venous thromboembolism for hospitalized medical patients with lung Cancer.Thrombosis journal · 2021Article
- The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLC.Respiratory research · 2020Article
- Increases in tumor markers are associated with primary Sjögren's syndrome-associated interstitial lung disease.Therapeutic advances in chronic disease · 2020Article
- Diagnosis Value of Combined Detection of Serum SF, CEA and CRP in Non-Small Cell Lung Cancer.Cancer management and research · 2020Article
- Evaluation of the HOXA11 level in patients with lung squamous cancer and insights into potential molecular pathways via bioinformatics analysis.World journal of surgical oncology · 2018Article
- Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review.Journal of Cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor markers (TMs) and D-Dimer are both hallmarks of severity and prognosis of lung cancer. Tumor markers could be related to pulmonary embolism (PE) in lung cancer.
resultsThe number of abnormal tumor markers of lung cancer patients with pulmonary embolism (3.9 ± 1.1vs1.6 ± 0.6,P 0.005) was more than that in patients without pulmonary embolism. TMs panel (P trend < 0.001), CEA (R2 0.735, P0.003) and CYFRA21-1 (R2 0.718, P0.005) were positively correlated with D-Dimer in patients with pulmonary embolism. The multivariate logistic regression analysis showed that, for tumor markers, TMs panel (OR5.98, P < 0.001) had the strongest correlation with pulmonary embolism. The AUC (area under curve) of TMs panel and CEA were 0.82 [95%CI (0.71-0.95), P < 0.001] and 0.71 [95%CI (0.62-0.84), P 0.002] by ROC (receiver operating characteristic) curve analysis, respectively. MATERIALS AND
methodsTumor markers were compared between lung cancer patients complicated with pulmonary embolism and those without pulmonary embolism Then the correlation between each tumor marker as well as panel of combined TMs and D-Dimer as well as pulmonary embolism were analyzed for patients with pulmonary embolism.
conclusionsThere is a relationship between tumor markers and pulmonary embolism in patients with lung cancer. The panel of combined tumor markers is a valuable diagnostic marker for pulmonary embolism in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.